A systematic review published on October 9, 2026 examines human pharmacokinetic, infant and lactation outcomes for ketamine and esketamine during breastfeeding (PMID 42850468; DOI 10.1007/s00228-026-04197-2).
Evidence level: abstract-only. We verified the NCBI/PubMed record and abstract, not the article's full text. This is a research notice about an existing review, not a new full meta-analysis by Conclave.
The authors included 16 reports; the milk pharmacokinetic studies involved nine participants and racemic ketamine. Results were not pooled because the studies were not sufficiently comparable. The abstract reports no infant plasma measurements or long-term neurodevelopmental outcomes, and no repeated intranasal esketamine exposure study. Its findings must not be extrapolated into established safety for repeated use or individual treatment advice. Important gaps remain.
Primary sources
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42850468&retmode=xml
Написать Join — чтобы участвовать в обсуждении.